
Operating expenses were driven by research and development expenses of $17.4M and general and administrative expenses of $6.0M. “The favorable safety, tolerability and PK results from the single ascending-dose portion
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TECX | Tectonic Therapeutic | 19.97 | 2.47 | 14.15% |
| Name | Price | % Change | |
|---|---|---|---|
| $19.97 | +14.15% |

Operating expenses were driven by research and development expenses of $17.4M and general and administrative expenses of $6.0M. “The favorable safety, tolerability and PK results from the single ascending-dose portion

Meeting to be held in New York on October 27 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

UBS analyst Alice Nettleton initiated coverage of Tectonic Therapeutic (TECX) with a Neutral rating and $26 price target The six-minute walk distance, which will likely be the key Phase 3

Tectonic Therapeutic ( ($TECX) ) just unveiled an update. On September 29, 2026, Tectonic Therapeutic reported favorable topline results from a Phase 1a first-in-human trial of TX2100 in 48 healthy

LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. Gaurav Maini has given his Buy rating due to a

Tectonic Therapeutic (TECX) announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational VHH-Fc fusion antagonist antibody targeting the APJ receptor, in healthy adult volunteers. The

LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic today and set a price target of $88.00. Gaurav Maini has given his Buy rating due to a

Tectonic Therapeutic ( ($TECX) ) has provided an announcement. On June 8, 2026, Tectonic Therapeutic, Inc. held its 2026 annual stockholders’ meeting, where shareholders elected Timothy A. Springer and Stefan

Tectonic Therapeutic (TECX) announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension

Raymond James analyst Martin Auster upgraded Tectonic Therapeutic (TECX) to Strong Buy from Outperform with a price target of $81, up from $76. The company offers an “uncommonly attractive opportunity,”
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Oct 15, 2026 | ||||
| hold | Initiated | Oct 11, 2026 | ||||
| buy | Assigned | Sep 29, 2026 | ||||
| buy | Reiterated | Sep 29, 2026 | ||||
| buy | Reiterated | Aug 10, 2026 | ||||
| buy | Reiterated | May 26, 2026 | ||||
| buy | Reiterated | May 8, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 25, 2027TBA | $418.51M | $-1.38 | $0.00 | -1.69 | -4.53 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.